Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Polycythemia Vera - Global Drug Pipeline Insight, 2026 | 25+ Therapies Drive JAK2-Targeted Innovation and Late-Stage Partnership Opportunities

globenewswire.com
INCY Incyte Corporation is mentioned as a key company profiling prominent products in the Polycythemia Vera pipeline, specifically INCB000928. The article does not provide specific sentiment on the company's performance or prospects. MRK Merck Sharp & Dohme LLC (a subsidiary of Merck & Co., Inc.) is listed as a key company profiling Bomedemstat, a late-stage product in the Polycythemia Vera pipeline. No specific sentiment is expressed about Merck's overall performance. PRLD Prelude Therapeutics is identified as a key company with an early-stage product (PRT12396) in the Polycythemia Vera pipeline. The article does not offer specific sentiment regarding the company's outlook. SLN Silence Therapeutics plc is mentioned as a key company involved in the Polycythemia Vera pipeline with product SLN-124. The article does not provide any sentiment regarding the company's performance or future prospects.

Polycythemia Vera - Global Drug Pipeline Insight, 2026 | 25+ Therapies Drive JAK2-Targeted Innovation and Late-Stage Partnership Opportunities Dublin, Oct. 22, 2026 (GLOBE NEWSWIRE) -- "Polycythemia Vera - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering.

The report delivers a comprehensive analysis of the global Polycythemia Vera pipeline, covering 20+ companies and 25+ investigational drugs across clinical, preclinical and discovery stages. It evaluates active and inactive pipeline products by development phase, product type, route of administration and molecule type, while examining the commercial and clinical prospects of emerging Polycythemia Vera therapies.

Polycythemia Vera Disease and Treatment Landscape

Polycythemia Vera is a myeloproliferative neoplasm characterized by uncontrolled red blood cell production and frequently accompanied by elevated white blood cell and platelet counts. Increased blood viscosity contributes to symptoms and complications such as headache, dizziness, claudication, thrombosis and bleeding.

Abnormal clonal stem cells in the bone marrow suppress normal stem cell growth and maturation. Mutations affecting Janus kinase-2 (JAK2) signaling are central to disease pathogenesis, with JAK2V617F identified in more than 90% of patients. This mutation results in constitutive cytokine receptor activity, promoting excessive blood cell production and increasing the risk of vascular and hematologic complications.

Diagnosis follows updated clinical criteria that consider elevated hemoglobin or hematocrit, bone marrow hypercellularity with trilineage proliferation, JAK2 mutation status and low serum erythropoietin levels. Secondary causes of polycythemia must be excluded. Current Polycythemia Vera treatment focuses on symptom control and reducing the risks of thrombosis, bleeding and progression to myelofibrosis, acute leukemia or myelodysplastic syndrome.

Polycythemia Vera Pipeline Analysis

The report provides detailed Polycythemia Vera drug profiles, including mechanisms of action, clinical study activity, regulatory developments and product advancement strategies. It also reviews collaborations, licensing agreements, mergers and acquisitions, funding, designations and other developments affecting Polycythemia Vera research and development.

The pipeline includes late-stage products in Phase III, mid-stage candidates in Phase II, early-stage therapies in Phase I, and Pre-clinical and Discovery stage programs. Discontinued and inactive candidates are also assessed to provide a complete view of development activity and competitive dynamics.

Selected Emerging Polycythemia Vera Drugs

Therapeutic Assessment and Market Scope

Pipeline therapies are categorized by route of administration, including oral, intravenous, subcutaneous, parenteral and topical products. Molecule types covered include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymers and gene therapies. The analysis also classifies products as Mono, Combination or Mono/Combination therapies.

Key companies profiled include Merck Sharp & Dohme LLC, Chengdu Zenitar Biomedical Technology Co., Ltd, Prelude Therapeutics, Italfarmaco, Mabwell (Shanghai) Bioscience Co., Ltd., Silence Therapeutics plc, Incyte Corporation, Hangzhou GluBio Pharmaceutical Co., Ltd., Ajax Therapeutics, Inc. and Syntara.

Prominent products in the Polycythemia Vera pipeline include Bomedemstat, Flonoltinib, PRT12396, Givinostat, 9MW3011, SLN-124, INCB000928, GLB-001, AJ1-11095 and PXS-5505.

Strategic Insights

The report examines unmet needs, emerging treatment approaches, clinical trial progress and the potential impact of pipeline drugs on the Polycythemia Vera treatment landscape. It also assesses Industry-Industry and Industry-Academia collaborations, licensing activity, acquisitions, novel technologies and regulatory designations. These insights support pharmaceutical companies, investors, researchers and other stakeholders seeking to understand competitive positioning, development opportunities and future growth prospects within the global Polycythemia Vera therapeutics market.

Key Topics Covered:

Introduction

Executive Summary

Polycythemia Vera: Overview

Pipeline Therapeutics

Therapeutic Assessment

Polycythemia Vera- Analytical Perspective

Late Stage Products (Phase III)

Bomedemstat: Merck Sharp & Dohme LLC

Mid Stage Products (Phase II)

Flonoltinib: Chengdu Zenitar Biomedical Technology Co., Ltd

Early Stage Products (Phase I)

PRT12396: Prelude Therapeutics

Preclinical and Discovery Stage Products

Inactive Products

Polycythemia Vera Key Companies

Polycythemia Vera Key Products

Polycythemia Vera- Unmet Needs

Polycythemia Vera- Market Drivers and Barriers

Polycythemia Vera- Future Perspectives and Conclusion

Polycythemia Vera Analyst Views

Appendix

List of Tables [12]

List of Figures [12]

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/xbmkv4

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.